Deepa V Cherla1, Noe A Rodriguez1,2, Roman Vangoitsenhoven1,3, Tavankit Singh4, Neal Mehta4, Arthur J McCullough4, Stacy A Brethauer1,5, Philip R Schauer1, Ali Aminian6. 1. Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, 9500 Euclid Avenue, Desk M61, Cleveland, OH, 44195, USA. 2. Department of General Surgery, Florida Atlantic University, Boca Raton, FL, USA. 3. Department of Endocrinology, UZLeuven, Leuven, Belgium. 4. Department of Gastroenterology, Cleveland Clinic, Cleveland, OH, USA. 5. Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 6. Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, 9500 Euclid Avenue, Desk M61, Cleveland, OH, 44195, USA. aminiaa@ccf.org.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome. Our aim was to study the long-term effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on NAFLD/NASH. METHODS: Between 2008 and 2015, 3813 patients had an intraoperative liver biopsy performed at the time of primary RYGB and SG at a single academic center. Utilizing strict inclusion criteria, 487 patients with biopsy-proven NAFLD who had abnormal alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values (≥ 40 IU/L) at baseline were identified. Matching of SG to RYGB patients (1:4) was performed via logistic regression and propensity scores adjusting for clinical and liver histological characteristics. Changes in liver function tests (LFTs) at least 1 year after surgery were compared to baseline values and between the surgical groups. RESULTS: A total of 310 (weighted) patients (SG n = 62, and RYGB n = 248) with a median follow-up time of 4 years (range, 1-10) were included in the analysis. The distribution of covariates was well-balanced after propensity matching. In 84% of patients, LFT values normalized after bariatric surgery at the last follow-up time. The proportions of patients having normalized LFT values did not differ significantly between the SG and RYGB groups (82% vs. 84%, p = 0.66). The AST decreased from (SG: 49.1 ± 21.5 vs. RYGB: 49.3 ± 22.0, p = 0.93) at baseline to (SG: 28.0 ± 16.5 vs. RYGB: 26.5 ± 15.5, p = 0.33) at the last follow-up. Similarly, a significant reduction in ALT values from (SG: 61.7 ± 30.0 vs. RYGB 59.4 ± 24.9, p = 0.75) at baseline to (SG: 27.2 ± 21.5 vs. RYGB: 26.1 ± 19.2, p = 0.52) at the last follow-up was observed. CONCLUSIONS: In patients with biopsy-proven NAFLD/NASH, abnormal LFTs are normalized in most SG and RYGB patients by the end of the first postoperative year and remain normal until the last follow-up. This study also suggests that both bariatric procedures are similarly effective in improving liver function.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome. Our aim was to study the long-term effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on NAFLD/NASH. METHODS: Between 2008 and 2015, 3813 patients had an intraoperative liver biopsy performed at the time of primary RYGB and SG at a single academic center. Utilizing strict inclusion criteria, 487 patients with biopsy-proven NAFLD who had abnormal alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values (≥ 40 IU/L) at baseline were identified. Matching of SG to RYGB patients (1:4) was performed via logistic regression and propensity scores adjusting for clinical and liver histological characteristics. Changes in liver function tests (LFTs) at least 1 year after surgery were compared to baseline values and between the surgical groups. RESULTS: A total of 310 (weighted) patients (SG n = 62, and RYGB n = 248) with a median follow-up time of 4 years (range, 1-10) were included in the analysis. The distribution of covariates was well-balanced after propensity matching. In 84% of patients, LFT values normalized after bariatric surgery at the last follow-up time. The proportions of patients having normalized LFT values did not differ significantly between the SG and RYGB groups (82% vs. 84%, p = 0.66). The AST decreased from (SG: 49.1 ± 21.5 vs. RYGB: 49.3 ± 22.0, p = 0.93) at baseline to (SG: 28.0 ± 16.5 vs. RYGB: 26.5 ± 15.5, p = 0.33) at the last follow-up. Similarly, a significant reduction in ALT values from (SG: 61.7 ± 30.0 vs. RYGB 59.4 ± 24.9, p = 0.75) at baseline to (SG: 27.2 ± 21.5 vs. RYGB: 26.1 ± 19.2, p = 0.52) at the last follow-up was observed. CONCLUSIONS: In patients with biopsy-proven NAFLD/NASH, abnormal LFTs are normalized in most SG and RYGB patients by the end of the first postoperative year and remain normal until the last follow-up. This study also suggests that both bariatric procedures are similarly effective in improving liver function.
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal Journal: Hepatology Date: 2017-09-29 Impact factor: 17.425
Authors: Ran B Luo; Toshiaki Suzuki; Jonathan C Hooker; Yesenia Covarrubias; Alexandra Schlein; Shanglei Liu; Jeffrey B Schwimmer; Scott B Reeder; Luke M Funk; Jacob A Greenberg; Guilherme M Campos; Bryan J Sandler; Santiago Horgan; Claude B Sirlin; Garth R Jacobsen Journal: Surg Endosc Date: 2017-12-07 Impact factor: 4.584
Authors: Witigo von Schönfels; Jan Henrik Beckmann; Markus Ahrens; Alexander Hendricks; Christoph Röcken; Silke Szymczak; Jochen Hampe; Clemens Schafmayer Journal: Surg Obes Relat Dis Date: 2018-07-24 Impact factor: 4.734
Authors: Carlos Martin Esquivel; Manuel Garcia; Lucas Armando; Guillermo Ortiz; Fernando Martínez Lascano; José María Foscarini Journal: Obes Surg Date: 2018-12 Impact factor: 4.129
Authors: Miller Barreto de Brito E Silva; Francisco Tustumi; Antonio Afonso de Miranda Neto; Anna Carolina Batista Dantas; Marco Aurélio Santo; Ivan Cecconello Journal: Obes Surg Date: 2021-04-13 Impact factor: 4.129
Authors: Sophia M-T Schmitz; Andreas Kroh; Alexander Koch; Jonathan F Brozat; Christine Stier; Ulf P Neumann; Tom F Ulmer; Patrick H Alizai Journal: Obes Surg Date: 2021-04-04 Impact factor: 4.129
Authors: Carolina M Perdomo; Javier Gómez-Ambrosi; Sara Becerril; Víctor Valentí; Rafael Moncada; Eva M Fernández-Sáez; Leire Méndez-Giménez; Silvia Ezquerro; Victoria Catalán; Camilo Silva; Javier Escalada; Gema Frühbeck; Amaia Rodríguez Journal: Int J Mol Sci Date: 2021-11-30 Impact factor: 5.923